Clinical Trial Update: Replagal Enzyme Replacement Therapy for Adults With Fabry Disease [Phase 4]

View source ↗

Summary

This update reports completion of a Phase 4 clinical trial evaluating Replagal enzyme replacement therapy in adults with Fabry disease.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Fabry Disease

Drugs mentioned

• Replagal (agalsidase alfa)

Snippet

Sponsor: National Institute of Neurological Disorders and Stroke (NINDS) | Conditions: Fabry Disease | Phase 4 | Status: COMPLETED